Patients with MS on fingolimod have dramatically reduced total circulating ILCs, with reductions of all ILC subsets (83), suggesting that S1PR1 modulators are efficacious in MS by inhibiting ILC (particularly ILC3) migration to CNS, thereby limiting Th17 infiltration. Here, CCL27 is linked to myeloid sarcoma.